AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03741842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMBO-KEY
Description: The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
Study NCT03461341 — intervention group
Intervention type: OTHER
Intervention: High intensity postoperative oncologic surveillance
Description: High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
Study NCT04358367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Product
Description: Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
Study NCT04358367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
Study NCT03910049 — intervention group
Intervention type: DRUG
Intervention: Indocyanine Green
Description: Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
Study NCT04000945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with BTL-899 device, 3 therapies
Study NCT04000945 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment with BTL-899 device, 3 visits
Study NCT03845049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
Study NCT02062684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Study NCT03845049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHAM injection
Description: Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
Study NCT03845049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Examinations during study (every month)
Description: visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
Study NCT03845049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examinations during study (every month)
Description: visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-Shot Propofol
Description: Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30min infusion Propofol
Description: 30min of propofol infusion (4-6mg/kg/h)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Description: Remifentanil infusion (0.1-0.2µg/kg/min)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Remifentanil infusion (0.1-0.2µg/kg/min)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.07mg/kg/body mass)
Description: Rocuronium (0.07mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.07mg/kg/body mass)
Description: Rocuronium (0.07mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.1mg/kg/body mass)
Description: Rocuronium (0.1mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.1mg/kg/body mass)
Description: Rocuronium (0.1mg/kg/body mass)
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.15mg/kg/body mass)
Description: Rocuronium (0.15mg/kg/body mass)
Study NCT03012880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT02805517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percuvance™ Percutaneous Surgical System
Description: Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
Study NCT01243151 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-04950615 (RN316)
Description: Infusion every week
Study NCT01243151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Infusion every week
Study NCT03012880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03240991 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
Study NCT02062684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04492293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: ICP-192 is a white, round, uncoated table
Study NCT00979615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCL (Patanase) Nasal Spray, 0.6%
Description: 2 sprays/ nostril BID
Study NCT00979615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine HCl (Astelin) Nasal Spray, 137 mcg
Description: 2 sprays/ nostril BID
Study NCT03019653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANX-042
Description: The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
Study NCT03019653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
Study NCT03288584 — intervention group
Intervention type: DRUG
Intervention: Other biological agent
Description: Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
Study NCT03584308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid®
Description: The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
Study NCT03584308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen®
Description: The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
Study NCT03584308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Viusid Placebo
Description: The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
Study NCT00003192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminocamptothecin
Study NCT01766089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
Study NCT01766089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
Study NCT03339765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Together serious game
Description: The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
Study NCT03012880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03012880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03012880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01584297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
Study NCT04189783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
Study NCT04189783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
Study NCT04189783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery
Study NCT04189783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery
Study NCT04189783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04189783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02268305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSM 1000mg twice a day (6000 mgs)
Description: MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
Study NCT02268305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules twice a day
Description: Placebo is a capsule filled with rice flour.
Study NCT03288584 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid and non-biological agents.
Description: Enhanced treatment with corticosteroid and non-biological agents.
Study NCT02571179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl 50 microg dose up to 250 microg
Description: When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
Study NCT00934531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline.
Study NCT00934531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline.
Study NCT03686202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-4
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
Study NCT00908908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
Study NCT03141307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EICI Movie
Description: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
Study NCT03141307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EICI App
Description: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
Study NCT03141307 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of care, paper-based brochure
Study NCT03406949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: obrindatamab
Description: B7-H3 x CD3 DART protein
Study NCT03406949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: anti-PD-1 antibody
Study NCT04791397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
Description: Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
Study NCT03584308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glizigen Placebo
Description: The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
Study NCT04065646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile
Study NCT04054258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App support Programme (ASP) group
Description: All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
Study NCT04054258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: App support Programme (ASP) group
Description: All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
Study NCT03226613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcervical Oropharyngeal Ultrasound
Description: One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
Study NCT03226613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Rinse Collection
Description: Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
Study NCT03226613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
Study NCT04791397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
Description: Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
Study NCT02260414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: single subcutaneous injection of 4500 IU tinzaparin
Study NCT02054468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.15mg/kg/body mass)
Description: Rocuronium (0.15mg/kg/body mass)
Study NCT02260414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: single subcutaneous injection of 4500 IU tinzaparin
Study NCT03012880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02994836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TNF: Infliximab (Infusion)
Description: Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
Study NCT02994836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF discontinuation: Physiological saline solution
Description: Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
Study NCT02994836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TNF:Adalimumab (Subcutaneus)
Description: Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
Study NCT02994836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-TNF discontinuation: Physiological saline solution
Description: Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
Study NCT03565562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of the e-health tool by local authorities
Description: Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.